EA006602B1 - Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций - Google Patents
Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций Download PDFInfo
- Publication number
- EA006602B1 EA006602B1 EA200400448A EA200400448A EA006602B1 EA 006602 B1 EA006602 B1 EA 006602B1 EA 200400448 A EA200400448 A EA 200400448A EA 200400448 A EA200400448 A EA 200400448A EA 006602 B1 EA006602 B1 EA 006602B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antigen
- vaccine
- type
- glycoconjugate
- polysaccharide
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 149
- 208000035143 Bacterial infection Diseases 0.000 title claims abstract description 16
- 208000022362 bacterial infectious disease Diseases 0.000 title claims abstract description 16
- 239000000427 antigen Substances 0.000 claims abstract description 154
- 108091007433 antigens Proteins 0.000 claims abstract description 154
- 102000036639 antigens Human genes 0.000 claims abstract description 154
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 52
- 239000005017 polysaccharide Substances 0.000 claims abstract description 52
- 230000001580 bacterial effect Effects 0.000 claims abstract description 22
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims abstract description 18
- 108010015899 Glycopeptides Proteins 0.000 claims abstract description 18
- 102000002068 Glycopeptides Human genes 0.000 claims abstract description 18
- 108010022457 polysaccharide peptide Proteins 0.000 claims abstract description 9
- 150000004804 polysaccharides Chemical class 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 43
- 208000031729 Bacteremia Diseases 0.000 claims description 38
- 206010061598 Immunodeficiency Diseases 0.000 claims description 36
- 208000015181 infectious disease Diseases 0.000 claims description 31
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 claims description 11
- 101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 claims description 11
- 101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 claims description 11
- 101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 150000002402 hexoses Chemical class 0.000 claims description 8
- 230000004523 agglutinating effect Effects 0.000 claims description 7
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 6
- 101710082714 Exotoxin A Proteins 0.000 claims description 6
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 6
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 6
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- MBLBDJOUHNCFQT-LXGUWJNJSA-N aldehydo-N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229930182830 galactose Natural products 0.000 claims description 6
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 6
- 150000004043 trisaccharides Chemical group 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 229920001284 acidic polysaccharide Polymers 0.000 claims description 4
- 150000004805 acidic polysaccharides Chemical class 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000028208 end stage renal disease Diseases 0.000 claims description 4
- 201000000523 end stage renal failure Diseases 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 3
- 229920002498 Beta-glucan Polymers 0.000 claims description 3
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002095 exotoxin Substances 0.000 claims description 2
- 231100000776 exotoxin Toxicity 0.000 claims description 2
- 206010049076 End stage AIDS Diseases 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 235000019410 glycyrrhizin Nutrition 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000012977 invasive surgical procedure Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 abstract description 3
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 description 27
- 239000000902 placebo Substances 0.000 description 27
- 238000001631 haemodialysis Methods 0.000 description 21
- 230000000322 hemodialysis Effects 0.000 description 21
- 230000028993 immune response Effects 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 238000002255 vaccination Methods 0.000 description 14
- 230000007423 decrease Effects 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 11
- 230000005847 immunogenicity Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 208000037157 Azotemia Diseases 0.000 description 6
- 108010060123 Conjugate Vaccines Proteins 0.000 description 6
- 206010041925 Staphylococcal infections Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940031670 conjugate vaccine Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- 208000009852 uremia Diseases 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 229940031416 bivalent vaccine Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229960003085 meticillin Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010014889 Enterococcal infections Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 206010011409 Cross infection Diseases 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 206010016717 Fistula Diseases 0.000 description 3
- 206010024769 Local reaction Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003890 fistula Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 208000004002 Vascular Fistula Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 230000000625 opsonophagocytic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- -1 1-cyano-4-dimethylaminopyridinium tetrafluoroborate Chemical compound 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001538234 Nala Species 0.000 description 1
- 240000008338 Nigella arvensis Species 0.000 description 1
- 235000007413 Nigella arvensis Nutrition 0.000 description 1
- 235000016698 Nigella sativa Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010051017 Staphylococcal bacteraemia Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044541 Traumatic shock Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/955,585 US20030113350A1 (en) | 2001-09-19 | 2001-09-19 | Glycoconjugate vaccines for use in immune-compromised populations |
| PCT/US2002/029601 WO2003061558A2 (en) | 2001-09-19 | 2002-09-19 | Glycoconjugate vaccines for use in immune-compromised populations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200400448A1 EA200400448A1 (ru) | 2004-12-30 |
| EA006602B1 true EA006602B1 (ru) | 2006-02-24 |
Family
ID=25497036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200400448A EA006602B1 (ru) | 2001-09-19 | 2002-09-19 | Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20030113350A1 (https=) |
| EP (1) | EP1427442A4 (https=) |
| JP (2) | JP2005515237A (https=) |
| KR (3) | KR101214766B1 (https=) |
| CN (1) | CN1306958C (https=) |
| CA (1) | CA2460749C (https=) |
| EA (1) | EA006602B1 (https=) |
| MX (1) | MXPA04002624A (https=) |
| NZ (1) | NZ548453A (https=) |
| WO (1) | WO2003061558A2 (https=) |
| ZA (1) | ZA200402185B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100217772B1 (ko) * | 1996-09-03 | 1999-09-01 | 최진호 | 조명기기의 램프 과열방지 장치 및 방법 |
| US20020092987A1 (en) * | 1998-09-05 | 2002-07-18 | Taehee Cho | Photo detect device using quantum dots and materialization method thereof |
| US6936258B1 (en) * | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| WO2004043405A2 (en) | 2002-11-12 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
| EP1567868A4 (en) * | 2002-12-02 | 2008-02-06 | Biosynexus Inc | CELL WALL TEICHONSURE AS A GOAL F RANTI-STAPHYLOCOCCUS THERAPIES AND VACCINATES |
| BRPI0408167B1 (pt) | 2003-03-07 | 2014-10-21 | Wyeth Corp | Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais |
| AU2011265368B9 (en) * | 2004-09-22 | 2012-11-29 | Biosynexus Incorporated | Immunogenic composition |
| KR20070058631A (ko) * | 2004-09-22 | 2007-06-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| US20060134141A1 (en) * | 2004-12-14 | 2006-06-22 | Nabi Biopharmaceuticals | Glycoconjugate vaccines containing peptidoglycan |
| EP1850867A1 (en) * | 2005-01-10 | 2007-11-07 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
| US20060228368A1 (en) * | 2005-04-07 | 2006-10-12 | Nabi Biopharmaceuticals | Method of protecting against staphylococcal infection |
| FR2884830A1 (fr) | 2005-04-25 | 2006-10-27 | Sanofi Pasteur Sa | Procede de production de souches de staphylococcus aureus surproductrices |
| AU2006275865B2 (en) * | 2005-07-29 | 2012-06-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Mutated Pseudomonas exotoxins with reduced antigenicity |
| MY148405A (en) * | 2006-03-30 | 2013-04-30 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| FR2899110A1 (fr) | 2006-03-31 | 2007-10-05 | Sanofi Pasteur Sa | Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus |
| GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| EP2185190B1 (en) * | 2007-08-31 | 2015-06-24 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| KR20110031393A (ko) * | 2008-07-21 | 2011-03-25 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물 |
| WO2010014304A1 (en) * | 2008-07-29 | 2010-02-04 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| ES2784957T3 (es) | 2009-04-03 | 2020-10-02 | Univ Chicago | Composiciones y métodos relacionados con variantes de la proteína A (SPA) |
| HUE036372T2 (hu) | 2009-06-22 | 2018-07-30 | Wyeth Llc | Staphylococcus aureus antigének immunogén készítményei |
| BRPI1011753B8 (pt) | 2009-06-22 | 2021-05-25 | Wyeth Llc | conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| US8974799B2 (en) | 2009-09-30 | 2015-03-10 | Novartis Ag | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
| BR112012010223A2 (pt) * | 2009-10-30 | 2016-12-06 | Novartis Ag | purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares |
| WO2011088843A1 (en) * | 2010-01-19 | 2011-07-28 | Universitätsklinikum Freiburg | Enterococcal cell wall components and antibacterial use thereof |
| JP6002128B2 (ja) | 2010-07-02 | 2016-10-05 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | プロテインＡ（ＳｐＡ）変種に関連する組成物および方法 |
| CN102565336A (zh) * | 2010-12-13 | 2012-07-11 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102539726A (zh) * | 2010-12-13 | 2012-07-04 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102565354A (zh) * | 2010-12-13 | 2012-07-11 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102539708A (zh) * | 2010-12-13 | 2012-07-04 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102565332A (zh) * | 2010-12-13 | 2012-07-11 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102539704A (zh) * | 2010-12-13 | 2012-07-04 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102539702A (zh) * | 2010-12-13 | 2012-07-04 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| EP2872535A1 (en) * | 2012-07-16 | 2015-05-20 | Pfizer Inc. | Saccharides and uses thereof |
| GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
| AU2015359503B2 (en) | 2014-12-10 | 2019-05-09 | Glaxosmithkline Biologicals Sa | Method of treatment |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| WO2020163512A1 (en) | 2019-02-05 | 2020-08-13 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
| MX2021013833A (es) | 2019-05-14 | 2022-03-17 | Univ Chicago | Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa). |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| WO2021041721A1 (en) * | 2019-08-27 | 2021-03-04 | OneBioPharma, Inc. | Antimicrobial vaccine compositions |
| WO2021051136A1 (en) | 2019-09-13 | 2021-03-18 | The University Of Chicago | Methods and compositions for treating staphylococcal infections |
| US20260007731A1 (en) * | 2022-01-05 | 2026-01-08 | Bluewillow Biologics, Inc. | Intranasal polysaccharide conjugate nanomulsion vaccines and methods of using the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747024A (en) * | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
| US5770208A (en) * | 1996-09-11 | 1998-06-23 | Nabi | Staphylococcus aureus B-linked hexosamine antigen |
-
2001
- 2001-09-19 US US09/955,585 patent/US20030113350A1/en not_active Abandoned
-
2002
- 2002-09-19 KR KR1020107005839A patent/KR101214766B1/ko not_active Expired - Lifetime
- 2002-09-19 MX MXPA04002624A patent/MXPA04002624A/es active IP Right Grant
- 2002-09-19 CN CNB028184238A patent/CN1306958C/zh not_active Expired - Lifetime
- 2002-09-19 KR KR10-2004-7003967A patent/KR20040070331A/ko not_active Ceased
- 2002-09-19 EP EP02806591A patent/EP1427442A4/en not_active Ceased
- 2002-09-19 JP JP2003561504A patent/JP2005515237A/ja active Pending
- 2002-09-19 CA CA2460749A patent/CA2460749C/en not_active Expired - Lifetime
- 2002-09-19 EA EA200400448A patent/EA006602B1/ru not_active IP Right Cessation
- 2002-09-19 WO PCT/US2002/029601 patent/WO2003061558A2/en not_active Ceased
- 2002-09-19 NZ NZ548453A patent/NZ548453A/en not_active IP Right Cessation
- 2002-09-19 KR KR1020087022908A patent/KR101090529B1/ko not_active Expired - Lifetime
-
2004
- 2004-03-18 ZA ZA2004/02185A patent/ZA200402185B/en unknown
-
2006
- 2006-01-25 US US11/338,900 patent/US7449189B2/en not_active Expired - Lifetime
-
2010
- 2010-07-08 JP JP2010155473A patent/JP2010265293A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080089527A (ko) | 2008-10-06 |
| KR101214766B1 (ko) | 2012-12-24 |
| ZA200402185B (en) | 2005-06-29 |
| KR20040070331A (ko) | 2004-08-07 |
| CA2460749A1 (en) | 2003-07-31 |
| CN1306958C (zh) | 2007-03-28 |
| WO2003061558A3 (en) | 2003-09-12 |
| US7449189B2 (en) | 2008-11-11 |
| NZ548453A (en) | 2007-07-27 |
| CN1638794A (zh) | 2005-07-13 |
| MXPA04002624A (es) | 2005-02-17 |
| JP2005515237A (ja) | 2005-05-26 |
| EP1427442A2 (en) | 2004-06-16 |
| US20060188518A1 (en) | 2006-08-24 |
| JP2010265293A (ja) | 2010-11-25 |
| KR101090529B1 (ko) | 2011-12-08 |
| CA2460749C (en) | 2012-10-23 |
| WO2003061558A9 (en) | 2004-06-10 |
| EA200400448A1 (ru) | 2004-12-30 |
| WO2003061558A2 (en) | 2003-07-31 |
| KR20100044265A (ko) | 2010-04-29 |
| EP1427442A4 (en) | 2006-06-21 |
| US20030113350A1 (en) | 2003-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA006602B1 (ru) | Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций | |
| US20230062987A1 (en) | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli | |
| Wessels et al. | Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine | |
| JP4764820B2 (ja) | ワクチン用担体タンパク質 | |
| FI110993B (fi) | Menetelmä B-ryhmän streptokokkityyppien II ja V polysakkaridi-proteiinikonjugaatin valmistamiseksi | |
| Paoletti et al. | Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines | |
| MX2007007090A (es) | Vacunas glicoconjugadas que contienen peptidoglicanos. | |
| WO1992016232A1 (en) | Polysaccharide-protein conjugates | |
| Cryz Jr et al. | Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines | |
| Paoletti et al. | Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons | |
| WO2005007804A2 (en) | Anthrax conjugate vaccine and antibodies | |
| AU2002365253B2 (en) | Glycoconjugate vaccines for use in immune-compromised populations | |
| NZ531647A (en) | Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections | |
| AU2002365253A1 (en) | Glycoconjugate vaccines for use in immune-compromised populations | |
| RU2780425C2 (ru) | Композиции neisseria meningitidis и способы | |
| AU662141C (en) | Polysaccharide-protein conjugates | |
| D'Cor et al. | Safety and Immunogenicity of a Cholera Conjugate Vaccine in Healthy South Korean Adults: A Phase 1 Dose-Escalation Trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |